GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells

Abstract

Eukaryotic initiation factor 5A2 (eIF5A2), a newly identified oncogene, promotes cell survival, proliferation and motility in tumorigenesis. Drug resistance and dose-related adverse side-effects greatly reduce the efficiency and safety of cisplatin-based chemotherapy in advanced or recurrent oral squamous cell carcinoma (OSCC) patients. The present study investigated the effect of eIF5A2 combined with N1-guanyl-1,7-diaminoheptane (GC7, a novel eIF5A2 inhibitor) or siRNA. We found that low concentrations of GC7 (≤5 µM) had little effect on OSCC cell viability, but significantly enhanced cisplatin cytotoxicity. Compared with cisplatin, GC7/cisplatin had little effect on cisplatin-promoted mesenchymal-epithelial transition in mesenchymal phenotype Tca8113 and HN30 cells, or on cisplatin-induced epithelial-mesenchymal transition (EMT) in epithelial phenotype Cal27 and HN4 cells. Further research revealed that the upregulation of p-STAT3 and c-Myc which was induced by the single treatment with either cisplatin or GC7 was significantly reversed by the GC7/cisplatin combination in mesenchymal phenotype Tca8113 and HN30 cells. In in vivo treatment, we revealed that the GC7/cisplatin combination presented significant tumor volume reduction without distinct body weight loss. In conclusion, our data indicated that eIF5A2 is a potent therapeutic target in OSCC treatment. Our results revealed a novel mechanism by which GC7/cisplatin combination therapy may offer an efficient and safe therapeutic alternative to advanced or recurrent OSCC patients.

WITHDRAWN: PYCR1 Promotes Proliferation, Invasion and Drug-Resistance of Lung Cancer Cells by Regulating STAT3-Mediated PI3K/AKT and NF-κB Signaling Pathway

“…Moreover, aberrant expression and constitutive activation of STAT3 have been detected in a variety of tumors such as the gastric cancer, breast cancer, prostate tumor, and NSCLC [13][14][15]. Additionally, knockdown of STAT3 was proved to be facilitate to enhance the chemotherapy e cacy of malignant cancer by inhibition cell proliferation, invasion, and inhibition of drug-resistance [16].…”

Combinatorial Low Dose Arsenic Trioxide and Cisplatin Exacerbates Autophagy via AMPK/STAT3 Signaling on Targeting Head and Neck Cancer Initiating Cells

“…Thus, STAT3 signaling has been chosen as cancer therapeutic target. STAT3 has been proposed as CDDP sensitivity converse key factor (54). There are reports showing some potential molecules could affect the JAK-STAT3 cancerous pathway (55) to promote cell apoptosis effects.…”

Finding new cancer epigenetic and genetic biomarkers from cell-free DNA by combining SALP-seq and machine learning

“…Furthermore, elevated expression of WHSC1 is often observed in many types of human cancers, and expression product of WHSC1 is essential for the growth of cancer cells [52] , [53] . The gene EIF5A2 was related to not only ESCA [54] , [55] , [56] , but also breast cancer [57] , lung cancer [58] , [59] , bladder cancer [60] , [61] , stomach cancer [62] , [63] , oral cancer [64] , liver cancer [65] , and colorectal cancer [66] . By checking the expression of these genes detected in tumors (RNA-seq data in TCGA), most of these genes are significantly up-regulated in tumors ( Figs.…”